Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.30 per share. This compares to earnings of $1.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.54%. A quarter ago, it was expected that this medicine distributor would post earnings of $1.16 per share when it actually produced earnings of $1.22, delivering a surprise of 5.17%.Over the last four ...

Full-Year Fiscal 2025 Results May 8th, 2025 Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, and free cash flow; the Company's reinvestment in Clear Eyes as supply increases; the Company's ability to execute on its brand- building strategy and to drive free cash flo ...

Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Cons ...

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings TARRYTOWN, N.Y.--(GLOBE NEWSWIRE)-May 8, 2025-- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which delivered another year of consistent sales and earnings per share growth. The record fourth quarter sales performance exceeded our expectations, driven by continued Internat ...

Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Cons ...

Access to the live question and answer session may be obtained by calling the operator at (289) 514-5100 / (800) 717-1738 (Conference ID: 07724) up to ten minutes prior to the scheduled start time. For those who are unable to participate, a recording of the question and answer session will be available through to 11:59 p.m. Toronto time on Saturday, June 7, 2025 at (289) 819-1325 / (888) 660-6264 (passcode: 07724#). Alternatively, a recording of the question and answer session will be available at the Compa ...

Core Viewpoint - Prestige Consumer Healthcare Inc. is set to release its fiscal 2025 fourth quarter and year-end earnings on May 8, 2025, before market opening, followed by a conference call at 8:30 a.m. ET to discuss the results [1]. Company Overview - Prestige Consumer Healthcare Inc. markets, sells, manufactures, and distributes a wide range of consumer healthcare products across the U.S., Canada, Australia, and other international markets [4]. - The company's diverse portfolio includes well-known brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon® in Canada, Hydralyte®, and the Fess® line of products in Australia [4].

Core Insights - Prestige Consumer Healthcare (PBH) is focused on brand building and portfolio expansion through strategic acquisitions, which is expected to drive growth in upcoming quarters [1][5] - The company has experienced a share price increase of 19.3% over the past year, outperforming the industry and S&P 500 [1] Company Overview - PBH has a market capitalization of $4.17 billion and reported an earnings surprise of 5.17% in the last quarter [2] - The earnings yield for PBH stands at 5.4%, significantly higher than the industry's 0.3% [2] Growth Drivers - The strength of PBH's diversified portfolio, which includes well-recognized consumer brands, has contributed to sales growth and long-term profitability, with core brands generating nearly 58.6% of total revenues in fiscal 2024 [3] - The gastrointestinal (GI) product category is a significant contributor, accounting for nearly 20% of North American sales, with brands like Dramamine, Fleet, and Gaviscon leading the category [4] - The company is also seeing growth in the e-commerce channel, reflecting a long-term trend towards online purchases [4] Strategic Acquisitions - PBH has expanded its brand portfolio through both organic growth and acquisitions, including the purchase of TheraTears and other over-the-counter brands from Akorn Operating Company LLC, as well as Hydralyte from Hydration Pharmaceuticals Trust [5] Financial Concerns - As of the end of the fiscal third quarter, PBH had a long-term debt of $996 million and cash and cash equivalents of $51 million, with a debt-to-capital ratio of 35.8% [7] - The company generated approximately 14.8% of its fiscal 2024 revenues from international business, making it susceptible to currency fluctuations [9] Earnings Estimates - The Zacks Consensus Estimate for PBH's fiscal 2025 earnings per share has increased by 0.4% to $4.52, with revenue estimates at $1.13 billion, reflecting a 0.5% increase from the previous year [10]

Core Viewpoint - Premium Brands Holdings Corporation has announced a bought-deal offering of $150 million in convertible unsecured subordinated debentures, with potential total gross proceeds of $172.5 million if the over-allotment option is exercised [1][2][3] Group 1: Offering Details - The company will issue $150,000,000 aggregate principal amount of convertible unsecured subordinated debentures at a price of $1,000 per debenture [1] - An over-allotment option allows underwriters to purchase an additional $22,500,000 in debentures, potentially raising total gross proceeds to $172,500,000 [1] - The closing of the offering is expected around March 19, 2025, subject to regulatory approvals [6] Group 2: Use of Proceeds - Net proceeds from the offering will be used to repay existing indebtedness under credit facilities, which will then be available for the redemption of the 4.65% debentures, future acquisitions, capital projects, and general corporate purposes [3] Group 3: Debenture Terms - The debentures will bear interest at 5.50% per annum, payable semi-annually, with a maturity date of March 31, 2030 [4] - Holders can convert the debentures into common shares at a conversion price of $126.15 per share, equating to 7.9271 shares for each $1,000 principal amount [5]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 reached $290 million, an increase of nearly 3% year-over-year, exceeding forecasts [8][19] - Earnings per share (EPS) increased by 15% to a record $1.22, driven by strong sales growth and lower interest expenses [9][20] - Free cash flow for the first nine months was $184.9 million, up 5% year-over-year, with a full-year outlook of $240 million or more [27][32] Business Line Data and Key Metrics Changes - The GI category, which includes brands like Dramamine, Fleet, and Gaviscon, represents nearly one-fifth of North American sales, showing solid mid-single-digit growth over the last three years [11][16] - International segment sales grew approximately 8% excluding foreign exchange, with Hydralyte being a key contributor [19][63] - The Cough & Cold category saw a decline, expected to be flat to down slightly for the year, impacting overall sales [44][46] Market Data and Key Metrics Changes - E-commerce sales continued to show double-digit year-over-year growth, indicating a long-term trend towards higher online purchasing [22] - The North American segment experienced broad-based growth, with notable increases in the GI category brands, partially offset by lower Cough & Cold sales [19][21] Company Strategy and Development Direction - The company is focused on capital deployment options to enhance shareholder value, including opportunistic share repurchases and potential M&A activities [10][29] - Management anticipates revenue for fiscal 2025 to be between $1.128 billion and $1.132 billion, with an organic revenue growth forecast of approximately 1% [30][32] - The company is well-positioned to manage inflation and tariff changes due to its diversified supply base and strong market share [24][49] Management's Comments on Operating Environment and Future Outlook - Management noted heightened uncertainty in the business environment due to supply chain constraints and inflation, but remains optimistic about the company's performance [5][30] - The company expects to see gradual improvements in sales for Clear Eyes as production levels increase and additional suppliers are added [37][56] - Management expressed confidence in the business momentum heading into fiscal 2026, with record sales and EPS reported [41][72] Other Important Information - The company reduced its variable term loan debt balance to zero and improved its leverage ratio to 2.5x [10][28] - Advertising and marketing expenses were 14.1% of sales for the first nine months, with expectations for an increase in dollars compared to the prior year [25] Q&A Session Summary Question: Recovery expectations for Clear Eyes - Management indicated that production levels for Clear Eyes were in line with expectations, with sales slightly ahead due to timing differences [36] Question: Clarity on Q4 gross margin expectations - Management explained that the anticipated gross margin increase in Q4 is driven by the timing of cost-saving initiatives [39] Question: Inventory levels in the Cold & Cough category - Management noted that the Cold & Cough category is not a significant part of their portfolio, and they do not expect a substantial increase in reorder rates [44][46] Question: Exposure to tariffs - Management stated that while they monitor tariff implications, the majority of manufacturing is in the U.S., providing a strategic advantage [49] Question: Promotional intensity for Clear Eyes - Management confirmed that Clear Eyes remains a leading brand, and they do not anticipate changes in promotional activity as they regain shelf space [54] Question: Future plans for Hydralyte - Management discussed the long-term brand building strategy for Hydralyte, emphasizing a slow build in new markets [58] Question: International growth outside Hydralyte - Management highlighted strong growth across various brands in the care business, not limited to Hydralyte [62] Question: Expansion into oral laxatives for Fleet - Management confirmed the launch of constipation-related products under the Fleet brand, connecting with consumers based on the brand's heritage [68] Question: Free cash flow guidance - Management maintained the free cash flow guidance of $240 million or more, feeling positive about cash flow performance [76] Question: Appetite for acquisitions - Management expressed a healthy appetite for M&A opportunities, remaining disciplined in their approach [81]